![]() ![]() In the open-label, dose-escalation, dose-expansion study of CLN-978 in patients with relapsed or refractory NHL, an estimated 90 patients will be enrolled at 1 of 5 centers across the United States. Recruitment Contact: Timna Serino, 6174104650, Date: November 2026 Trial Name: AA Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)Ĭ Identifier: NCT05879744 Collectively, these features may open up opportunities to investigate CLN-978 in additional CD19-mediated disease…” CLN-978 also offers patient-friendly administration and potentially reduced toxicity with an off-the-shelf treatment that is delivered subcutaneously. Based on preclinical evidence, we believe CLN-978 has a differentiated profile as it binds with very high affinity to CD19-expressing cells, even those with barely detectable levels of CD19. “T cell engagers have shown clinical activity in this patient population, and CD19 is a well-validated target for B-cell malignancies. “Despite recent advances in treating B-NHL, there remains significant unmet medical need, particularly among patients with relapsed/refractory disease,” said Jeffrey Jones, MD, MPH, MBA, chief medical officer, Cullinan Oncology, in a press release. Together, these abilities enable T-cell activation and apoptosis of malignant tumors that express CD19. It also has VHH, an antibody that allows for binding to human serum albumin. One fragment binds to CD19 on malignant tumors, and the other to CD3 on T cells. The agent has 2 single-chain variable fragments. 1Īccording to Cullinan Oncology, Inc, developer of CLN-978, the agent is a CD19/CD3 T-cell engaging antibody that may be an alternative to chimeric antigen receptor (CAR) T agents on the market. The first patient has been administered CLN-978 as part of a first-in-human study of the drug in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL NCT05879744). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |